MA56041A - Compositions comprenant des acides gras cétylés, destinées à être utilisées dans le traitement de la muqueuse gastrique, du diabète et de l'hyperglycémie - Google Patents

Compositions comprenant des acides gras cétylés, destinées à être utilisées dans le traitement de la muqueuse gastrique, du diabète et de l'hyperglycémie

Info

Publication number
MA56041A
MA56041A MA056041A MA56041A MA56041A MA 56041 A MA56041 A MA 56041A MA 056041 A MA056041 A MA 056041A MA 56041 A MA56041 A MA 56041A MA 56041 A MA56041 A MA 56041A
Authority
MA
Morocco
Prior art keywords
hyperglycemia
diabetes
compositions
treatment
fatty acids
Prior art date
Application number
MA056041A
Other languages
English (en)
Inventor
Elisa Brilli
Andrea Lacorte
Germano Tarantino
Original Assignee
Alesco Srl
Pharmanutra S P A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alesco Srl, Pharmanutra S P A filed Critical Alesco Srl
Publication of MA56041A publication Critical patent/MA56041A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/231—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having one or two double bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23B—PRESERVATION OF FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES; CHEMICAL RIPENING OF FRUIT OR VEGETABLES
    • A23B2/00—Preservation of foods or foodstuffs, in general
    • A23B2/70—Preservation of foods or foodstuffs, in general by treatment with chemicals
    • A23B2/725—Preservation of foods or foodstuffs, in general by treatment with chemicals in the form of liquids or solids
    • A23B2/729—Organic compounds; Microorganisms; Enzymes
    • A23B2/742—Organic compounds containing oxygen
    • A23B2/746—Organic compounds containing oxygen with singly-bound oxygen
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
    • A23L2/52—Adding ingredients
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A61K8/347—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A61K8/361—Carboxylic acids having more than seven carbon atoms in an unbroken chain; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
    • A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/10—General cosmetic use
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/52—Stabilizers
    • A61K2800/522—Antioxidants; Radical scavengers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Food Science & Technology (AREA)
  • Birds (AREA)
  • Nutrition Science (AREA)
  • Rheumatology (AREA)
  • Polymers & Plastics (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
MA056041A 2019-05-27 2020-05-27 Compositions comprenant des acides gras cétylés, destinées à être utilisées dans le traitement de la muqueuse gastrique, du diabète et de l'hyperglycémie MA56041A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT102019000007329A IT201900007329A1 (it) 2019-05-27 2019-05-27 Composizioni comprendenti acidi grassi cetilati per uso nel trattamento della mucosa gastrica, diabete e alti livelli di glicemia

Publications (1)

Publication Number Publication Date
MA56041A true MA56041A (fr) 2022-04-06

Family

ID=67957312

Family Applications (1)

Application Number Title Priority Date Filing Date
MA056041A MA56041A (fr) 2019-05-27 2020-05-27 Compositions comprenant des acides gras cétylés, destinées à être utilisées dans le traitement de la muqueuse gastrique, du diabète et de l'hyperglycémie

Country Status (6)

Country Link
US (1) US12691091B2 (fr)
EP (1) EP3976023B1 (fr)
CN (1) CN114126602A (fr)
IT (1) IT201900007329A1 (fr)
MA (1) MA56041A (fr)
WO (1) WO2020240441A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT201700089258A1 (it) 2017-08-02 2019-02-02 Pharmanutra S P A Composizione per uso nella prevenzione e nel trattamento di carenza di ferro
IT201900007326A1 (it) 2019-05-27 2020-11-27 Alesco Srl Composizioni comprendenti acidi grassi cetilati e loro uso nel trattamento di artriti e stati infiammatori articolari
IT201900007329A1 (it) 2019-05-27 2020-11-27 Alesco Srl Composizioni comprendenti acidi grassi cetilati per uso nel trattamento della mucosa gastrica, diabete e alti livelli di glicemia
IT201900007311A1 (it) 2019-05-27 2020-11-27 Alesco Srl Procedimento per la preparazione di una composizione comprendente acidi grassi cetilati

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4049824A (en) 1976-05-03 1977-09-20 Harry Weldon Diehl Cetyl myristoleate
US4393133A (en) 1980-06-12 1983-07-12 The Wistar Institute Of Anatomy And Biology Human hepatoma derived cell line, process for preparation thereof, and uses therefor
JPH0244806B2 (ja) 1981-09-07 1990-10-05 Sunstar Kk Bitaminaoanteinihaigoshitanyukakeihifugaiyozaisoseibutsu
JPS6351312A (ja) 1986-08-20 1988-03-04 Pola Chem Ind Inc 美肌化粧料
JPH04154724A (ja) 1990-10-18 1992-05-27 Green Cross Corp:The 活性型ビタミンd↓3化合物含有脂肪乳剤
JP3860849B2 (ja) 1994-04-28 2006-12-20 エーザイ・アール・アンド・ディー・マネジメント株式会社 抗動脈硬化治療剤
EP0679394B1 (fr) 1994-04-28 1998-01-14 Eisai Co., Ltd. Dérivé du Menatetrenome comme agent antiartériosclérotique
US6461622B2 (en) 1994-09-07 2002-10-08 Johnson & Johnson Consumer Companies, Inc. Topical compositions
CA2222278C (fr) 1995-06-06 2008-05-13 Campbell Soup Company Complements alimentaires a base de mineraux pour repas dietetique
US5707670A (en) 1996-08-29 1998-01-13 The Procter & Gamble Company Use of bilayer forming emulsifiers in nutritional compositions comprising divalent mineral salts to minimize off-tastes and interactions with other dietary components
CU22723A1 (es) * 1997-04-02 2002-02-28 Dalmer Lab Sa Mezcla de ácidos grasos primarios de alto peso molecular obtenidos de la cera de cana de azúcar y sus usos farmacéuticos
NZ332959A (en) 1998-11-23 2001-09-28 Yasho Ind Pvt Ltd Preparation of cetyl myristate and cetyl palmitate
US6417227B1 (en) * 1999-04-28 2002-07-09 Cg And Associates Methods of delivery of cetyl myristoleate
US6361800B1 (en) 2000-04-13 2002-03-26 Cooper Concepts, Inc. Multi-vitamin and mineral supplement
AU2001290367B2 (en) 2001-08-31 2008-06-19 Lypanosys Pte Limited Synthesis of ester linked long chain alkyl moieties
JP2003342159A (ja) 2002-03-18 2003-12-03 Nikko Chemical Co Ltd 皮膚老化防止化粧料
US7772279B2 (en) 2002-03-21 2010-08-10 Botanoceuticals, Inc. Use of vegetable butter-based cetyl myristoleate for treating osteoarthritis and other musculoskeletal disease conditions and injuries
GB0220182D0 (en) 2002-08-30 2002-10-09 Cardiovascular Res Inst Maastr Organic compounds
AU2004224332A1 (en) 2003-03-20 2004-10-07 Imagenetix, Inc. Esterified fatty acid composition
AU2004287440A1 (en) 2003-10-28 2005-05-19 Emory University Dialysates and methods and systems related thereto
US20050100636A1 (en) 2003-11-10 2005-05-12 Megan Botteri [A Low-Calorie Sports Drink For Physically Active Women That is Fortified with Iron, Calcium and Essential Vitamins for Use in Rehydration and Replacing Electrolytes Lost During Periods of Physical Activity]
US7585527B2 (en) 2005-09-19 2009-09-08 Bala Venkataraman Composition and method for treating iron deficiency anemia
EP1790356A1 (fr) 2005-11-24 2007-05-30 Vifor (International) Ag Préparation contenant des complexes de fer(III) et des composés rédoxs
ES2634142T3 (es) 2005-12-23 2017-09-26 Ajay Gupta Composición de nutrición parenteral que contiene hierro
EP1978808B1 (fr) 2006-01-30 2018-08-29 Panion & BF Biotech Inc. Citrate de fer pour inverser, prévenir, retarder ou stabiliser la calcification des tissus mous
ITMI20080145A1 (it) 2008-01-30 2009-07-31 Pharmanutra S R L Uso di acido eicosapentanoico e/o docosaesanoico in donne con endometriosi
US20100021573A1 (en) 2008-07-22 2010-01-28 Michael J Gonzalez Compositions and methods for the prevention of cardiovascular disease
JPWO2010073642A1 (ja) 2008-12-25 2012-06-07 有限会社 アイ・ビー・イー 生物活性剤、医薬、化粧品、鮮度保持剤、および植物および動物の発育促進剤
CN102348482B (zh) 2009-01-12 2014-05-14 科学与工业研究委员会 用于制备顺式-9-十四碳烯酸十六烷基酯和顺式-10-十四碳烯酸十六烷基酯的方法
KR20100111040A (ko) * 2009-04-06 2010-10-14 정시남 지방산 계열 화합물을 유효성분으로 함유하는 위장 질환 예방 또는 치료용 조성물
US8404745B2 (en) 2011-03-16 2013-03-26 Raj R. Barathur Transdermal delivery of medicinal cetylated fatty esters using phonophoresis or iontophoresis
CN103687495A (zh) 2011-05-20 2014-03-26 弗里斯兰品牌有限公司 包含维生素k2的组合物
US20140121156A1 (en) 2011-06-13 2014-05-01 Entia Biosciences, Inc. Nutritional approach to the control of anemia, diabetes and other diseases or conditions and prevention of associated comorbid states with the use of ergothioneine
US8183227B1 (en) 2011-07-07 2012-05-22 Chemo S. A. France Compositions, kits and methods for nutrition supplementation
ITMI20121350A1 (it) 2012-07-31 2014-02-01 Alesco Srl Composizione solido a base di ferro per uso nelle condizioni di deficienza di ferro.
WO2014160279A1 (fr) 2013-03-13 2014-10-02 Viroxis Corporation Formulations de crème stabilisées comprenant de l'essence de santal
US20140322314A1 (en) * 2013-04-29 2014-10-30 Matinas Biopharma, Inc. Omega-3 Fatty Acid Formulations for Use as Pharmaceutical Treatment
EP2886129A1 (fr) 2013-12-20 2015-06-24 VitaK B.V. Prévention et action contraire de risque de thrombose induite par le régime alimentaire
US9861611B2 (en) 2014-09-18 2018-01-09 Virun, Inc. Formulations of water-soluble derivatives of vitamin E and soft gel compositions, concentrates and powders containing same
EP3258924A2 (fr) 2015-02-20 2017-12-27 VitaK B.V. Statut en vitamine k et fonction capillaire
ITUB20153130A1 (it) 2015-08-14 2017-02-14 Pharmanutra S P A Acidi grassi cetilati, impianto per la loro preparazione e relativo uso
US9579357B1 (en) 2015-08-31 2017-02-28 Anc Products, Llc Therapeutic compositions
US10206949B2 (en) * 2015-09-21 2019-02-19 Ofer Agam Composition that relieves heartburn, GERD and hangovers
US20170202802A1 (en) 2016-01-20 2017-07-20 Exeltis Usa, Inc. Compositions, kits and methods for nutrition supplementation
GB2552952B (en) 2016-08-12 2020-03-04 Norbrook Lab Ltd Moxidectin topical liquid formulations
US11344575B2 (en) 2016-08-15 2022-05-31 Summit Innovation Labs, LLC Vascular calcification prevention and treatment
CN106343566A (zh) 2016-08-30 2017-01-25 李洋 一种慢性肾病患者用的特殊医用食品配方及其生产工艺
EP3632406B1 (fr) 2017-05-30 2024-03-13 The Nisshin OilliO Group, Ltd. Hydratant huileux et composition topique pour la peau le contenant
IT201700085412A1 (it) 2017-07-26 2019-01-26 Pharmanutra S P A Composizione per uso nella prevenzione e nel trattamento di patologie dell'apparato cardiovascolare
IT201700089258A1 (it) 2017-08-02 2019-02-02 Pharmanutra S P A Composizione per uso nella prevenzione e nel trattamento di carenza di ferro
IT201900007326A1 (it) 2019-05-27 2020-11-27 Alesco Srl Composizioni comprendenti acidi grassi cetilati e loro uso nel trattamento di artriti e stati infiammatori articolari
IT201900007311A1 (it) 2019-05-27 2020-11-27 Alesco Srl Procedimento per la preparazione di una composizione comprendente acidi grassi cetilati
IT201900007329A1 (it) 2019-05-27 2020-11-27 Alesco Srl Composizioni comprendenti acidi grassi cetilati per uso nel trattamento della mucosa gastrica, diabete e alti livelli di glicemia
IT202300004227A1 (it) 2023-03-07 2024-09-07 Pharmanutra S P A Composizioni comprendenti acidi grassi cetilati e vitamina d, e loro usi relativi

Also Published As

Publication number Publication date
EP3976023A1 (fr) 2022-04-06
WO2020240441A1 (fr) 2020-12-03
EP3976023C0 (fr) 2025-07-02
CN114126602A (zh) 2022-03-01
EP3976023B1 (fr) 2025-07-02
US20220226274A1 (en) 2022-07-21
US12691091B2 (en) 2026-07-28
IT201900007329A1 (it) 2020-11-27

Similar Documents

Publication Publication Date Title
EP2214480A4 (fr) Procédés de traitement d'une stéatohépatite non alcoolique au moyen de produits à base de cystéamine
RU2018110647A (ru) Арильные, гетероарильные и гетероциклические соединения для лечения заболеваний
MX2009005279A (es) Derivados de n-(metil)-1h-pirazol-3-amina, n-(metil)-piridin-2-ami na y n-(metil)-tiazol-2-amina para el tratamiento de enfermedades asociadas con proteinas amiloides o tipo amiloide, tal como por ejemplo alzheimer.
EA201790124A1 (ru) Соли берберина, соли урсодезоксихолевой кислоты и их комбинации, способы получения и применения
AR070561A1 (es) Anillos intravaginales monoliticos que comprenden progesterona y metodos para su fabricacion y uso
EA201070121A1 (ru) Лекарственная форма, содержащая слитый белок glp-1-fc
JP2015517459A5 (fr)
JP2019529541A5 (fr)
EP1562897A4 (fr) Inhibiteurs de beta-secretase phenylcarboxamide utilises dans le traitement de la maladie d'alzheimer
MA56040A (fr) Compositions comprenant des acides gras cétylés et leur utilisation dans le traitement de l'arthrite et des états inflammatoires articulaires
EP3848025C0 (fr) Compositions comprenant des acides aminés destinés à être utilisés dans la prévention et le traitement des effets secondaires de la chimiothérapie
IL265761B2 (en) Oral terlipressin compositions for use in treatment of ascites
EP3740225C0 (fr) Molécule de liaison à l'acide sialique destinée à être utilisée dans le traitement de la maladie du virus respiratoire syncytial (vrs)
EA200901237A1 (ru) Применение димирацетама при лечении хронической боли
EP3768274A4 (fr) Composition destinée à être utilisée dans le traitement d'états provoqués par une déficience en calcium
EP4048245A4 (fr) Compositions de cannabidiol destinées à être utilisées dans le traitement de pathologies cardiaques
EP3795170C0 (fr) Composition pharmaceutique comprenant du ccn5 utilisé comme ingrédient efficace pour la prévention ou le traitement d'une maladie rétinienne
EP3766503A4 (fr) Application d'un inhibiteur de micro-arn-210 dans la préparation de médicaments destinés au traitement de maladies cutanées inflammatoires
EP2231148A4 (fr) Composition pharmaceutique utilisée dans le traitement et la prévention d'une maladie cardiaque
EP3813868A4 (fr) Régimes posologiques pour l'inhibition ciblée de tgf-? destinée à être utilisée dans le traitement du cancer chez des sujets vierges de tout traitement
JP2008533079A5 (fr)
EP2329819A4 (fr) Composition pharmaceutique destinée à être utilisée dans le traitement des infections sexuellement transmissibles
MA54276B1 (fr) Montélukast destinée au traitement de l'arthrose de la main
EP4007580C0 (fr) Composition comprenant des dérivés de stérols pour son utilisation dans le traitement d'une pathologie neuronale liée à une hypoxie, à une hypoglycémie et/ou une hyperglycémie
BRPI0602397C1 (pt) composições farmacêuticas para o tratamento das doenças gordurosas do fìgado, obesidade e demais doenças associadas à sìndrome metabólica e métodos de tratamento utilizando-se as referidas composições